A doctor holds a Regeneron monoclonal antibody infusion bag during a news conference Thursday, Aug. 19, 2021 at a hospital in Fort Lauderdale, Fla. On Monday, Jan. 24, 2022, the Food and Drug Administration said COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the dominant omicron variant. (Joe Cavaretta/South Florida Sun-Sentinel via AP) **FILE**
Featured Photo Galleries
